Tomas Pokrivcak, MD, PhD· @pokrivcak · X·· 2 天前评分45
正文 · 原文
Will PAPMET 2 change the guidelines for metastatic papillary RCC?
Cabozantinib remains the preferred option, but IO–TKI combinations look promising.
Tomorrow at #ESMO2026: randomized results of cabozantinib ± atezolizumab.
#PAPMET2 #KidneyCancer
21 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Tomas Pokrivcak, MD, PhD · x.com